B. John Lindeman
elected B. John Lindeman to serve as a member of the Board
Highest-materiality recent filing
On July 2, 2026, Nasdaq determined Hydrofarm did not meet terms of extension to regain compliance with $2.5M minimum stockholders' equity rule.
Hydrofarm shareholders elect director, approve say-on-pay, ratify auditor at annual meeting
Director Richard Christopher Yetter elected with 1,716,445 votes for, 252,583 withheld (673,928 broker non-votes).
Hydrofarm gets Nasdaq extension to meet equity rule; must close strategic deals
Nasdaq granted extension until Q3 2026 filing (Sept 30, 2026) to regain compliance with Listing Rule 5550(b).
Hydrofarm Q1 net sales down 29.6% to $28.5M; Term Loan default triggers forbearance
Net loss of $14.6M ($3.07 diluted EPS) vs. $14.4M loss ($3.12 EPS) in prior year.
Hydrofarm Holdings Group replaces auditor: Deloitte out, CBIZ in
Dismissed Deloitte & Touche LLP as independent auditor, effective April 14, 2026.
Hydrofarm defaults on interest payment, enters forbearance agreement through April 30
Missed interest payment on $114.4M term loan (due Jan 31, 2026) led to default; forbearance until April 30, 2026.
Hydrofarm receives Nasdaq delisting notice over stockholders' deficit of $63.3M
Stockholders' deficit of $63.296M as of Dec 31, 2025, below Nasdaq's $2.5M minimum.
Hydrofarm defaults on Term Loan interest; Q4 net loss $242.2M includes $232.2M impairment
Q4 net sales fell 32.7% to $25.1M from $37.3M; volume/mix down 27.3%.
Hydrofarm terminates revolver, defers $2.8M interest; event of default on $125M term loan
Terminated Revolving Credit Agreement with JPMorgan as of Feb 17, 2026.
Hydrofarm Q3 net sales down 33% to $29.4M; CEO Lindeman resigns, Toler returns Dec 1
Net sales fell 33.3% to $29.4M; net loss widened to $16.4M ($3.51 loss per share) from $13.1M.
Hydrofarm director Susan Peters retires; Chris Yetter appointed to board effective Oct 1, 2025
Susan Peters retired effective Oct 1, 2025; no disagreement with company.
Hydrofarm Q2 net sales down 28.4% to $39.2M; net loss $16.9M; initiates restructuring plan
Net sales $39.2M, down 28.4% YoY from $54.8M; net loss $16.9M ($3.63/diluted share).
Hydrofarm retires Series A Preferred Stock; CEO Lindeman joins board after annual meeting
Retired 7,725,045 shares of Series A Preferred Stock, reducing authorized shares to 7,274,955.
Hydrofarm Q1 net sales $40.5M, down 25% YoY; withdraws FY2025 outlook
Net loss $14.4M ($3.12/sh) vs $12.6M ($2.75/sh) YoY; Adj. EBITDA -$2.4M vs +$0.3M.
CEO severance amended; change-of-control benefits enhanced
Cash severance increased to greater of $237,500 or 6 months base salary on termination without cause.
Hydrofarm Q4 net sales down 21% to $37.3M; net loss $17.5M; guides 2025 sales down 10-20%
Q4 net sales $37.3M (-20.9% YoY); Q4 net loss $17.5M ($3.80 diluted EPS) vs $15.2M loss prior year.
Hydrofarm effects 1-for-10 reverse stock split to meet Nasdaq $1 bid requirement
1-for-10 reverse split effective 5:00 PM ET Feb 12, 2025; adjusted trading begins Feb 13 under same symbol HYFM.
Hydrofarm Q3 net sales down 18.8% to $44M, loss improves to $13.1M
Net sales $44.0M (-18.8% YoY); net loss $13.1M ($0.29/share) vs $19.9M loss prior year.
Hydrofarm announces CEO succession: Toler to Executive Chairman, Lindeman to CEO as of Jan 1, 2025
William Toler retires as CEO effective Jan 1, 2025, becomes Executive Chairman; receives 350,000 RSUs.
Nasdaq granted 180-day extension to March 10, 2025 to comply with $1.00 minimum bid price rule.
Hydrofarm Q2 net sales down 13.1% to $54.8M; net loss widens to $23.5M
Net sales $54.8M vs $63.1M; net loss $23.5M ($0.51/sh) vs $12.9M ($0.28/sh) YoY.
Hydrofarm annual meeting votes: reverse stock split authorized, directors reelected
Shareholders approved amendment authorizing reverse stock split at ratio between 1:1.1 and 1:25.
Hydrofarm Q1 net sales $54.2M, net loss $0.28/sh; Adj EBITDA positive $0.3M; reaffirms FY outlook
Net sales $54.2M, down 13% YoY on volume decline; Adj gross margin improved to 23.4%.
Hydrofarm receives Nasdaq delisting notice for bid price below $1.00
Nasdaq notified Hydrofarm on March 14, 2024, that its common stock has not met the $1.00 minimum bid price for 30 consecutive business days.
Hydrofarm Q4 net loss improves to $15.2M; FY2023 adj EBITDA turns positive to $0.3M
Q4 net sales $47.2M, down 23% YoY from $61.5M; volume declined 18.7%, price/mix down 4.5%.
Hydrofarm Q3 net sales down 27% to $54.2M; adjusted EBITDA turns positive at $0.5M
Net sales $54.2M, down from $74.2M YoY; net loss $19.9M ($0.44/share).
Hydrofarm files amended 8-K/A to correct Item 2.02 tag and signature date; Q2 results unchanged
Amendment adds omitted Item 2.02 tag and corrects signature date from May 10 to Aug 9, 2023.
Hydrofarm Q2 net sales down 35% to $63.1M; posts positive Adjusted EBITDA $2.5M, updates FY outlook
Net sales $63.1M vs $97.5M YoY; volume decline 32.5% due to cannabis oversupply.
Hydrofarm amends credit agreement to replace LIBOR with SOFR, spreads unchanged
Amended $125M term loan to replace LIBOR with SOFR-based rates effective June 27, 2023.
Hydrofarm annual meeting results: certificate amendment fails, directors elected
Amendment to certificate of incorporation for officer exculpation failed; 16.6M for, but 22.7M majority of outstanding shares required.
Hydrofarm Q1 sales drop 44% to $62.2M; Adjusted EBITDA turns negative at $(2.1)M
Net loss narrowed to $(16.8)M ($(0.37)/diluted share) from $(23.3)M ($(0.52)) a year ago.
Hydrofarm Holdings amends credit facility, extends maturity to 2026, reduces commitment to $55M
Entered Fifth Amendment to Senior Secured Revolving Credit Facility with JPMorgan Chase, extending maturity to June 30, 2026.
Hydrofarm Q4 sales drop 44% to $61.5M; net loss widens; FY23 outlook modestly positive EBITDA
Q4 net sales $61.5M, down 44% YoY; net loss $(35.3)M vs $(11.0)M.
Hydrofarm reduces revolver to $75M, enters sale-leaseback of Oregon property for ~$8.6M
Fourth Amendment cuts revolving credit facility from $100M to $75M; no borrowings outstanding.
Company filed an 8-K under Item 7.01 announcing an updated investor presentation posted on its website.
Hydrofarm Q3 net sales down 40% to $74.2M; reaffirms FY2022 outlook
Net loss of $23.5M ($0.52 EPS loss) vs prior year net income of $17.3M; adjusted EPS loss of $0.33.
Hydrofarm Q2 net loss $203.3M; revenue down 27%; reiterates lowered outlook
Net sales fell 27% to $97.5M from $133.8M; volume down ~30% on hydroponic industry recession.
Hydrofarm expects Q2 net sales $96-97.5M, net loss up to $210M; cuts FY2022 guidance
Net sales $96-97.5M, down ~28% YoY; net loss $200-210M including $189.6M goodwill impairment.
Hydrofarm President Terence Fitch departs effective June 24, 2022
Terence Fitch steps down as President effective June 24, 2022, by mutual agreement.
Renah Persofsky and Melisa Denis re-elected as Class II directors; votes: 16.7M and 18.3M for respectively, 6.9M broker non-votes.
Hydrofarm Q1 net loss $23.3M; adjusted EPS -$0.17 vs +$0.18 YoY; updates FY2022 outlook
Net sales flat at $111.4M; gross profit fell to $16.6M (14.9% margin) from $23.2M (21.0%).
Hydrofarm CAO Joseph Rumley resigns; Kevin O'Brien appointed as successor
Joseph Rumley resigned as Chief Accounting Officer effective March 21, 2022, by mutual agreement.
Hydrofarm Q4 sales up 26%, FY net income $13.4M; guides FY2022 $575M-$615M rev
Q4 net sales $110.4M (+26.3% YoY); gross profit $18.7M (+16.7%).
Hydrofarm reaffirms FY2021 outlook; Q4 organic sales decline low-to-mid teens
Reaffirms FY2021 net sales $470-490M (37-43% YoY growth) and Adj. EBITDA $47-53M.
Hydrofarm releases inaugural 2020 ESG Sustainability Report
First ESG report covering 2020 initiatives; framework to guide future sustainability strategy.
Hydrofarm Q3 net sales rise 28% to $123.8M; adj. EBITDA +117%; reaffirms FY outlook
Net sales $123.8M (+28.1% YoY); gross profit $30.0M (24.2% margin vs 18.8%).
Hydrofarm completes $58M acquisition of IGE (horticulture equipment)
Closed acquisition of Innovative Growers Equipment (IGE) on Nov 1, 2021 for ~$58M.
Hydrofarm acquires IGE for $58M; preliminary Q3 sales ~$122.5M, raises FY2021 guidance
Acquires Innovative Growers Equipment (IGE) for ~$58M (cash+stock); IGE expected $48M sales in 2021; ~7x EBITDA multiple.
Hydrofarm increases revolving credit facility to $100M from $50M
Revolver limit doubled to $100M via amendment with JPMorgan Chase; $20M drawn as of Aug 31, 2021.
Hydrofarm Q2 net sales up 47% to $133.8M; adjusted EBITDA doubles to $16.2M; raises FY outlook
Net sales $133.8M (+46.7% YoY); gross margin improved 250 bps to 22.1%.
elected B. John Lindeman to serve as a member of the Board
vacancy left by Mr. Richard D. Moss following his resignation immediately prior to the 2025 annual meeting of stockholders
William Toler will retire from his position as Chief Executive Officer and become Executive Chairman of the Board.
B. John Lindeman will assume the role of Chief Executive Officer and Principal Executive Officer and no longer serve in his current position as Executive Vice President & Chief Financial Officer.
Mark Parker will assume the role of President and no longer serve in his current position as Executive Vice President of Sales and Business Development.
On June 22, 2022, Hydrofarm Holdings Group, Inc. (the “Company”) and Mr. Terence Fitch, the Company’s President, mutually agreed to Mr. Fitch’s departure as President, effective June 24, 2022.
On March 21, 2022, Hydrofarm Holdings Group, Inc. (the “Company”) and Mr. Joseph Rumley, the Company’s Chief Accounting Officer, mutually agreed to Mr. Rumley’s resignation as Chief Accounting Officer, effective immediately.
On March 21, 2022, the Company appointed Mr. Kevin O’Brien, 42, as the Company’s Chief Accounting Officer, effective as of the same date.
On July 12, 2021, Hydrofarm Holdings Group , Inc. (the “Company”) appointed Mr. Joseph Rumley, 62, as the Company’s Chief Accounting Officer, effective as of the same date.
Max materiality 0.95 · Median 0.70 · Most common event earnings